高盛:升中生製藥(1177.HK)目標價至10港元 評級“中性”
高盛發表報告指,中生製藥(01177.HK)今年第三季銷售達68億元人民幣,優於該行預測的63億元人民幣,主要是受腫瘤藥銷售(按年上升31.1%至16億元人民幣)的勢頭持續所推動。不過,集團季度純利為8.11億元人民幣,較該行預期為低,主因行政費用及税務開支增加,以及少數股東權益較高。
高盛表示,內地實行全國性的藥品集中採購政策,或對中生製藥的總銷售造成威脅,而該行對集團明年的仿製藥銷售仍然審慎,因集中採購政策對集團旗下藥品「潤眾」、「替諾福韋」及其他仿製藥的銷售會造成影響。
該行微調對中生製藥今年至2021年的每股盈測,其中2021年預測上調6.9%,以反映肺癌藥「安羅替尼」及其他新藥的銷售強勁提升。至於集團股份目標價由9.2港元升至10港元,評級維持“中性”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.